Altimmune (NASDAQ:ALT - Get Free Report) was downgraded by analysts at Guggenheim from a "buy" rating to a "neutral" rating in a research report issued to clients and investors on Monday, Marketbeat Ratings reports.
Several other research analysts have also issued reports on the stock. The Goldman Sachs Group initiated coverage on shares of Altimmune in a research report on Wednesday, January 24th. They issued a "neutral" rating and a $13.00 price target for the company. HC Wainwright dropped their price objective on shares of Altimmune from $15.00 to $12.00 and set a "buy" rating for the company in a report on Monday, April 1st. Finally, B. Riley reissued a "buy" rating and issued a $20.00 price target on shares of Altimmune in a report on Thursday, March 28th.
View Our Latest Stock Report on Altimmune
Altimmune Stock Performance
Shares of NASDAQ ALT traded down $0.87 during mid-day trading on Monday, reaching $6.40. The company had a trading volume of 4,920,032 shares, compared to its average volume of 5,310,766. The stock has a market capitalization of $453.34 million, a PE ratio of -4.02 and a beta of 0.05. Altimmune has a twelve month low of $2.09 and a twelve month high of $14.84. The stock's 50 day moving average is $9.28 and its 200-day moving average is $7.59.
Altimmune (NASDAQ:ALT - Get Free Report) last released its earnings results on Wednesday, March 27th. The company reported ($0.33) earnings per share for the quarter, beating the consensus estimate of ($0.35) by $0.02. Altimmune had a negative net margin of 20,780.75% and a negative return on equity of 44.77%. The business had revenue of $0.04 million during the quarter. On average, sell-side analysts anticipate that Altimmune will post -1.52 EPS for the current year.
Institutional Investors Weigh In On Altimmune
Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. SG Americas Securities LLC increased its stake in shares of Altimmune by 63.1% during the 3rd quarter. SG Americas Securities LLC now owns 43,086 shares of the company's stock worth $112,000 after purchasing an additional 16,661 shares during the last quarter. Miracle Mile Advisors LLC acquired a new position in shares of Altimmune during the 3rd quarter worth about $44,000. Barclays PLC increased its stake in shares of Altimmune by 62.0% during the 3rd quarter. Barclays PLC now owns 180,409 shares of the company's stock worth $470,000 after purchasing an additional 69,014 shares during the last quarter. Quantbot Technologies LP acquired a new position in shares of Altimmune during the 3rd quarter worth about $40,000. Finally, WealthPlan Investment Management LLC acquired a new position in shares of Altimmune during the 3rd quarter worth about $31,000. 78.05% of the stock is currently owned by institutional investors and hedge funds.
Altimmune Company Profile
(
Get Free Report)
Altimmune, Inc, a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis.
See Also
Before you consider Altimmune, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Altimmune wasn't on the list.
While Altimmune currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.
Get This Free Report
